Literature DB >> 25069847

[Pleural mesothelioma. Cytology and molecular diagnostics].

T Vlajnic1, S Savic, L Bubendorf.   

Abstract

The definitive diagnosis of malignant mesothelioma (MM) in effusion cytology is often avoided or reluctantly made by cytology alone. The most probable reason for this skepticism is the lack of expertise in cytology among many pathologists and clinicians. When an effusion specimen is composed of cells with unequivocal cytological features of malignancy that have the morphology and immunophenotype of mesothelial cells, the cytological diagnosis of MM is straightforward. However, in the daily routine difficult cases of atypical mesothelial cells are often encountered and additional methods are required to establish an accurate diagnosis. In contrast to reactive mesothelial cells cells of MMs often harbor chromosomal aberrations, most frequently a polysomy in combination with a 9p21 deletion. These chromosomal aberrations can easily be detected by multitarget fluorescence in situ hybridization (FISH); therefore, FISH allows a reliable distinction between reactive mesothelial cells and MM cells. In order to be able to discriminate between MM and adenocarcinoma, an immunocytochemical panel consisting of different mesothelial and epithelial markers is very helpful. In most inconclusive cases of atypical mesothelial cells the combination of morphology, immunocytochemistry and FISH allows a better distinction between reactive mesothelial cells and MM in effusion cytology.

Entities:  

Mesh:

Year:  2014        PMID: 25069847     DOI: 10.1007/s00292-014-1922-2

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  21 in total

Review 1.  The cytology of malignant mesothelioma.

Authors:  D Whitaker
Journal:  Cytopathology       Date:  2000-06       Impact factor: 2.073

2.  p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma.

Authors:  Harry Hwang; Christopher Tse; Stephanie Rodriguez; Allen Gown; Andrew Churg
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

Review 3.  Cytogenetic and molecular genetic changes in malignant mesothelioma.

Authors:  Marina Musti; Eeva Kettunen; Silvano Dragonieri; Pamela Lindholm; Domenica Cavone; Gabriella Serio; Sakari Knuutila
Journal:  Cancer Genet Cytogenet       Date:  2006-10-01

4.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.

Authors:  Peter B Illei; Valerie W Rusch; Maureen F Zakowski; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

5.  Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.

Authors:  Spasenija Savic; Noreli Franco; Bruno Grilli; Audrey de Vito Barascud; Michelle Herzog; Beata Bode; Heinz Loosli; Peter Spieler; René Schönegg; Inti Zlobec; Douglas P Clark; James G Herman; Lukas Bubendorf
Journal:  Chest       Date:  2010-02-05       Impact factor: 9.410

Review 6.  Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.

Authors:  Saul Suster; Cesar A Moran
Journal:  Adv Anat Pathol       Date:  2006-11       Impact factor: 3.875

7.  Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

Authors:  Aliya N Husain; Thomas Colby; Nelson Ordonez; Thomas Krausz; Richard Attanoos; Mary Beth Beasley; Alain C Borczuk; Kelly Butnor; Philip T Cagle; Lucian R Chirieac; Andrew Churg; Sanja Dacic; Armando Fraire; Francoise Galateau-Salle; Allen Gibbs; Allen Gown; Samuel Hammar; Leslie Litzky; Alberto M Marchevsky; Andrew G Nicholson; Victor Roggli; William D Travis; Mark Wick
Journal:  Arch Pathol Lab Med       Date:  2012-08-28       Impact factor: 5.534

8.  The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.

Authors:  Ajit Paintal; Kirtee Raparia; Maureen F Zakowski; Ritu Nayar
Journal:  Cancer Cytopathol       Date:  2013-09-04       Impact factor: 5.284

9.  Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.

Authors:  Carmen Flores-Staino; Eva Darai-Ramqvist; Katalin Dobra; Anders Hjerpe
Journal:  Lung Cancer       Date:  2009-06-12       Impact factor: 5.705

10.  [Fluorescence in situ hybridization. A new diagnostic dimension in cytology].

Authors:  S Savic; L Bubendorf
Journal:  Pathologe       Date:  2007-09       Impact factor: 0.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.